

1 **Title:** Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges,
2 adjacent and distant lung tissues

3 **Authors and Institution:** Qikang Hu^{1,2,4#}, Yang Gao^{3,5,6,7#}, Meredith Frank^{8#}, Liyan Ji⁹,
4 Muyun Peng^{1,2,4}, Chen Chen^{1,2,4}, Bin Wang^{1,2,4}, Yan Hu^{1,2,4}, Zeyu Wu^{1,2,4}, Jina Li^{1,2,4}, Lu
5 Shu^{1,2,4}, Qiongzhi He⁹, Yingqian Zhang⁹, Xuefeng Xia⁹, Jianjun Zhang⁸, Xin Yi^{9*},
6 Alexandre Reuben^{8*}, Fenglei Yu^{1,2,4*}

7 ¹Department of Thoracic Surgery, The Second Xiangya Hospital of Central South
8 University, Changsha, P. R. China

9 ²Hunan Key Laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The
10 Second Xiangya Hospital of Central South University, Changsha, China

11 ³Department of Thoracic Surgery, Xiangya Hospital, Central South University,
12 Changsha, P. R. China;

13 ⁴Early-Stage Lung Cancer Center, The Second Xiangya Hospital of Central South
14 University, Changsha, China

15 ⁵Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha,
16 China;

17 ⁶Hunan Engineering Research Center for Pulmonary Nodules Precise Diagnosis &
18 Treatment, Changsha, China ;

19 ⁷National Clinical Research Center for Geriatric Disorders, Changsha, China.

Spatial heterogeneity of T cell across NSCLC tissues

20 ⁸Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD

21 Anderson Cancer Center, Houston/United States of America

22 ⁹Geneplus-Beijing Institute, Beijing/China

23 **Abstract**

24 **Background:** A better understanding of the T cells in lung cancer and their distribution
25 across tumor-adjacent lungs and the peripheral blood is needed to improve efficacy and
26 minimize toxicity from immunotherapy to lung cancer patients.

27 **Methods:** Here, we performed CDR3 β TCR sequencing of 143 samples from 21 patients
28 with early-stage NSCLC including peripheral blood mononuclear cells, tumor, tumor
29 edges (<1cm from tumor), as well as adjacent lungs 1cm, 2cm, 5cm, and 10cm away
30 from the tumor to gain insight into the spatial heterogeneity of T cells across the lungs in
31 patients with NSCLC. PD-L1, CD4 and CD8 expression was assessed by
32 immunohistochemical staining and genomic features were derived by targeted sequencing
33 of 1,021 cancer related genes.

34 **Results:** Our study reveals a decreasing gradient in TIL homology with the tumor-edge,
35 adjacent lungs, and peripheral blood but no discernible distance-associated patterns of T
36 cell trafficking within the adjacent lung itself. Furthermore, we show a decrease in
37 pathogen-specific TCRs in regions with high T cell clonality and PD-L1 expression.

38 **Conclusions:** The exclusion in T cells at play across the lungs of patients with NSCLC
39 may be potentially the mechanism for lung cancer occurrence.

40 **Keywords:** T cell repertoire, NSCLC, IHC

Spatial heterogeneity of T cell across NSCLC tissues

41

42

Spatial heterogeneity of T cell across NSCLC tissues

43 **Introduction**

44 Lung cancer is the leading cause of cancer-related deaths and is expected to claim
45 over 130,000 lives in the US in 2022 alone[1] ([https://www.cancer.org/research/cancer-](https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html)
46 [facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html](https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html)). About 85% of
47 lung cancer diagnoses are classified as non-small cell lung cancer (NSCLC)[1, 2]. While
48 treatments for early-stage NSCLC bode decent success rates, 75% of patients present
49 with late-stage diseases at the time of diagnosis, for which survival rates are poor[2, 3].
50 Immunotherapies, such as immune checkpoint blockade (ICB) or adoptive cell therapy
51 (ACT) using autologous T cells, have led to substantial clinical benefit, yet a majority of
52 patients do not respond to treatment or develop secondary resistance[4, 5]. On the other
53 hand, although it is overall better tolerated than conventional chemotherapy, ICB can lead
54 to serious toxicities, some of which can be lethal. These have prompted exploration into
55 immune-related drivers of suboptimal responses and toxicities to identify biomarkers to
56 stratify patients for more personalized treatments.

57 PD-L1 is a widely used predictive marker. However, application across large patient
58 datasets has resulted in inconsistent predictive power[6]. Tumor mutational burden
59 (TMB) is another biomarker associated with efficacious responses to ICB and adoptive
60 transfer of expanded autologous CD8⁺ T cells[7, 8]. NSCLC tumors with higher TMB
61 generally have better clinical responses to ICB, perhaps due to a larger pool of neoantigen
62 targets for CD8⁺ T cell recognition[6, 9-11].

63 CD8⁺ T cells are critical mediators of anti-tumor responses as multiple groups have
64 shown that higher numbers of CD8⁺ tumor infiltrating lymphocytes (TIL) are associated
65 with improved outcomes[12, 13]. More specifically, recent work from our group

Spatial heterogeneity of T cell across NSCLC tissues

66 identified intratumor differences in the T cell repertoire as prognostic tools in NSCLC.
67 Multi-region TCR sequencing revealed that greater TCR ITH was associated with greater
68 risk of relapse and higher intratumor ITH in clonality was associated with more
69 aggressive disease progression and greater risk of relapse[4]. Our more recent work
70 demonstrated a high proportion of TCR overlap between the tumor and adjacent healthy
71 lung tissue and greater TCR overlap was associated with worse survival[14]. In these
72 studies, we determined that by analyzing the homology in T cell repertoire between
73 tumors and their adjacent lungs, we could identify T cells more likely to recognize viral
74 antigens (bystander T cells), and that these bystander T cells were associated with worse
75 outcome. However, in our prior studies, we were not able to assess any spatial differences
76 in the T cell repertoire of tumor-adjacent lungs based on proximity to the tumor[14].
77 Here, we used a step-wise approach to deconstruct the T cell repertoire architecture
78 across 6 regions within NSCLC tumor tissue and the surrounding healthy lung tissue. T
79 cell markers and repertoire metrics were compared across resected tissue from the tumor,
80 tumor edge (<1cm from tumor), and 1, 2, 5, and 10 cm away from the tumor across 21
81 lung adenocarcinoma patients in order to better understand the impact of the tumor on the
82 T cell repertoire across the lungs.

83 **Materials and Methods**

84 Tissue collection

85 Tissue samples from a total of 21 patients with primary lung cancer were
86 collected at Second Xiangya Hospital of Central South University from September to
87 December 2018. All patients gave written informed consent. The study was approved by
88 the Ethics Committee of Second Xiangya Hospital Central South University (IRB:

Spatial heterogeneity of T cell across NSCLC tissues

89 2020084). Tissues from tumor, tumor edge (defined as <1 cm away from tumor), 1 cm
90 away from tumor, 2 cm away from tumor, 5 cm away from tumor, 10 cm away from
91 tumor were collected for each patient during resection.

92 Targeted sequencing

93 DNA was extracted from FFPE of tumor tissues using Promega Maxwell™ RSC
94 DNA FFPE Kit (Lot: AS1135#847221). Blood DNA was used as control. DNA (0.8-1.0
95 µg) was sheared into fragments with a peak of 200-250 bp for library preparation using
96 NEBNext® Ultra™ DNA Library Prep Kit (NEB, Ipswich, MA). The barcoded libraries
97 were captured by a customized panel of 1021 genes as previously described[15].
98 Sequencing was performed on a GeneSeq2000 (Suzhou GenePlus Clinical Laboratory
99 Co, Suzhou, China) platform. Reads with low-quality (a. read with a half bases with
100 quality ≤ 5 ; b. reads with N base $\geq 5\%$; c. reads with average base quality < 0) were
101 removed from raw sequencing data. Then clean reads were mapped into hg19 human
102 genome using bwa, and reads were further analyzed through sentieon pipeline. Somatic
103 single nucleotide variations and small indels were called by MuTect2 and TNscope,
104 respectively. Final SNVs and indels were filtered by variant allele frequency $\geq 1\%$.

105 T cell receptor sequencing

106 Sequencing for human TCR β chain complementarities determining region 3
107 (CDR3) was performed as previously described[16]. Briefly, V and J genes of CDR3
108 gDNA were amplified with multi-plex primers. The PCR products were sequenced after
109 fragment selection by Illumina platform with paired-end 100bp. The clean data were
110 obtained by removal of low-quality reads. Paired-end reads were used for MIXCR to map

Spatial heterogeneity of T cell across NSCLC tissues

111 into V and J genes and annotated using ImMunoGeneTics (IMGT) database. Pathogen
112 associated TCRs were clustered by GLIPH2[17] using pathogen-related Mc-PAS dataset.

113 Immunohistochemistry

114 Tumor tissue PD-L1 was stained by PD-L1 (SP263) antibody (Roche).
115 Experiments were performed as manufacture's instruction. Positive PD-L1 staining
116 defined as 1) >25% of tumor cells exhibit positive membrane staining 2) immune cells
117 present (ICP) >1% and IC positive $\geq 25\%$ or 3) ICP = 1% and IC⁺ = 100%. The IHC
118 results for PD-L1 were viewed by independent two pathologists and averaged together
119 for analysis. CD4⁺ and CD8⁺ antibodies were provided from Servicebio Inc (Wuhan,
120 China). Immunohistochemistry score of CD4 and CD8 positive staining were quantified
121 by artificial intelligence-assistant IHC scoring system (Servicebio Inc, Wuhan, China).

122 Statistical analysis

123 All the statistics and graphs were analyzed by R (v 4.1.0). The Mann-Whitney U
124 test was used to determine the differences of numerous continuous data between groups.
125 Correlation was performed by Spearman coefficient. Paired t-tests and 2-way ANOVA
126 were used when appropriate. Significant differences were considered if $p < 0.05$.

127 **Results**

128 **Study design and patient cohort**

129 To investigate the spatial T cell composition of the tumor and adjacent lung
130 microenvironments, we enrolled a cohort of 21 patients with primary lung tumors (**Fig.**
131 **1A-B**). Patients had early-stage (stage I-III) NSCLC and underwent lobectomies for

Spatial heterogeneity of T cell across NSCLC tissues

132 curative intent. Targeted sequencing was performed to evaluate the genomic landscape,
133 and revealed a high prevalence of *TP53* mutations (55%, 11/20 patients), *EGFR*
134 mutations (45%, 9/20 patients), and *ZFH3* (20%, 4/20 patients) among others (**Fig. 1C**).
135 No differences in T cell repertoire were observed based on mutational landscape nor
136 smoking status (**Supplementary Fig. 1-2**). Clonality and diversity were compared across
137 all tissues for smokers versus non-smokers with no differences seen between the two
138 groups across all tissue samples (**Supplementary Fig. 2**).

139 **Increasing gradient of CD8⁺ and PD-L1⁺ observed in tumor periphery**

140 Previous studies in NSCLC have demonstrated that greater CD8⁺ T cell densities
141 within the tumor and tumor edge are associated with increased overall survival and,
142 conversely, higher CD4⁺ T cell densities are associated with worsened survival [12, 13].
143 Accordingly, we assessed changes in CD8⁺ and CD4⁺ T cell densities within tumor
144 tissue and peripheral regions by immunohistochemistry. No significant difference in
145 CD8⁺ or CD4⁺ T cell densities was observed between tumor tissue and peripheral regions
146 (**Fig. 2A-D**). However, the CD8⁺:CD4⁺ ratio was higher in the tumor edge, when
147 compared with the tumor itself, indicating the presence of CD8⁺-rich regions in the tumor
148 periphery (**Fig. 2E**). PD-L1 expression was also measured by immunohistochemistry but
149 revealed no differences between regions. However, overall tumor peripheral regions
150 exhibited higher PD-L1 expression on immune cells when compared to the tumor itself
151 (**Fig. 2F-G**).

152 **Regions of T cell high diversity exhibited lowest clonality and PD-L1 expression**

Spatial heterogeneity of T cell across NSCLC tissues

153 To assess the spatial distribution of T cell repertoire, we performed sequencing of
154 the CDR3 β region of the T cell receptor primarily involved in antigen binding and
155 analyzed related TCR metrics, namely, clonality and diversity. Clonality was calculated
156 across regions for 21 patients (**Fig. 3A**). Tumor tissue exhibited the lowest level of
157 clonality but highest level of diversity, whereas peripheral regions, namely 2 cm ($p= 4.9^{e-}$
158 7), contained higher clonality but lower amounts of diversity, consistent with prior studies
159 by our group[14] and suggestive of a suppressed T cell repertoire within the tumor
160 microenvironment ($p<0.05$) (**Fig. 3B-C**). PD-L1 expression was moderately associated
161 with clonality ($\rho= 0.43$, $p= 0.0178$), namely at 1 cm away from the tumor ($R= 0.62$,
162 $p= 0.26$) (**Fig. 3D-E**). No significant correlation was observed between clonality and
163 CD8 $^+$ density across all tissues (**Supplementary Fig. 3**).

164 **Dominant T cell populations are better conserved in tumor margins compared to**
165 **inside the tumors**

166 Morisita overlap index (MOI) values were calculated between all available
167 regions for 21 patients. As shown in **Supplementary Fig. 4**, substantial interpatient
168 heterogeneity was observed among samples. As expected, lower amount of overlap was
169 seen between tumor tissue and all other tissues, with a modest overlap only with the
170 tumor edge (**Fig. 3F**) (MOI=0.36). Most patients exhibited the highest overlap between
171 2cm and surrounding regions, namely 5cm, 1cm and the tumor edge (**Fig. 3F**)
172 (MOI=0.56, 0.54, and 0.58 respectively). In general, dominant T cell populations were
173 better conserved between the tumor margins and “hot regions” of increased clonality
174 compared to the tumors (**Fig. 3F**).

175 **High clonality regions are infiltrated by fewer predicted pathogen-specific T cells**

Spatial heterogeneity of T cell across NSCLC tissues

176 As large numbers of bystander T cells in tumor tissue have been identified in
177 NSCLC and other solid tumors[14, 18, 19], we next analyzed the pathogen-specificity
178 within tissue regions. GLIPH analysis was used to cluster similar CDR3 motifs which
179 were cross-referenced against publicly available viral CDR3 motifs to predict viral
180 antigen-specificity. Predicted pathogen TCR counts were calculated for all regions across
181 21 patients (**Fig. 4A**). Pathogen-specific TCR counts varied significantly between regions
182 with tumor tissue containing the highest proportion of pathogen-specific TCRs (**Fig. 4B**).
183 Clonality was inversely proportional to pathogen count ($R=-0.3$, $p= 0.00081$, **Fig. 4C**
184 **and Supplementary Fig. 5**). Interestingly, 2cm away from the tumor contained the
185 highest clonality and also exhibited a strong negative association between amount of
186 predicted pathogen TCRs and CD8⁺ density ($R=-0.87$, $p= 0.054$), but not CD4⁺ cell
187 density ($R=0.58$, $p= 0.3$), potentially suggesting preferential expansion of non-viral CD8⁺
188 T cells close to tumor edge (**Supplementary Fig. 6**). In tumor tissue, no correlation was
189 observed between CD4⁺ T cell density and the amount of predicted pathogen TCRs (**Fig.**
190 **4D**). In tumor tissues, the amount of pathogen-specific TCRs negatively correlated with
191 TCR clonality (**Fig. 4E**) but positively with CD8⁺ T cell density (**Fig. 4F**) indicating the
192 presence, but lack of expansion, of pathogen-specific T cells within the tumor (**Fig. 4F**).
193 A moderate, but not statistically-significant, association was observed between the
194 proportion of predicted pathogen TCRs and tumor cell PD-L1 expression ($R= 0.43$,
195 $p=0.059$) (**Fig. 4G**).

196 Discussion

197 Checkpoint blockade immunotherapy reactivates T cells exhibiting a given phenotype at
198 the systemic level, regardless of antigen-specificity[20]. Considering PD-1 is

Spatial heterogeneity of T cell across NSCLC tissues

199 indiscriminately expressed on T cells following antigen exposure, reactivation of these T
200 cells may be suboptimal[21]. Thus, a better understanding of the T cell repertoire in the
201 context of the lungs is needed. Here, we performed TCR sequencing on a series of
202 matched samples from 21 patients with early-stage NSCLC. To assess T cell infiltration
203 across the lungs, we obtained samples from tumors, tumor edges, as well as 1cm, 2cm,
204 5cm, and 10cm stepping away from the tumor in addition to from matched peripheral
205 blood.

206 Our spatial analysis of T cell infiltration allowed us to assess spatial T cell
207 distribution across the lungs. Although tumors and adjacent lungs have previously been
208 compared by us and others, such a dissection of the lung spatial environment and its T
209 cell infiltrate and repertoire has not yet been undertaken[14]. Analysis of the homology in
210 the T cell repertoire between the tumor and adjacent lung regions proved consistent with
211 our prior findings. Indeed, MOI between the tumor and adjacent lung was ~ 0.28 ,
212 consistent with a prior study by our group demonstrating a median of ~ 0.3 between
213 tumors and adjacent lungs[14]. The same could be said for MOI between the tumor and
214 peripheral blood, which was ~ 0.18 in our study and ~ 0.15 in the same prior study[14].
215 However, an important dimension not captured in our prior study was the inclusion of the
216 tumor edge, which showed the highest homology with the tumor, highlighting the overall
217 decreasing gradient in T cell homology from the tumor edge (MOI=0.36), to adjacent
218 lung (0.28), and peripheral blood (0.18). MOI between tumor and tumor edge was also
219 below what was observed in our prior analysis of intratumor heterogeneity (MOI=0.85),
220 as should be expected[4]. The lower homology between the tumor and all regions of the
221 adjacent lungs is suggestive of the potential presence of immune and T cell exclusion

Spatial heterogeneity of T cell across NSCLC tissues

222 mechanisms within the tumor, which prevent T cell infiltration and could therefore
223 explain the higher homology outside the tumor[22, 23].

224 Our analysis revealed increased T cell diversity and decreased T cell clonality in
225 the tumor compared to the tumor edge and adjacent lungs. This supports prior studies by
226 our group in larger cohorts with a lower spatial resolution[14]. Interestingly, by using
227 GLIPH2.0[17], we demonstrate that regions with the highest clonality also present the
228 lowest number of predicted pathogen-specific TCRs. This lack of predicted pathogen-
229 specific TCRs could suggest a higher probability of infiltration with tumor-specific
230 TCRs. Although this could be influenced by the increased diversity in pathogen TCR-rich
231 regions, positive correlation between PD-L1 and T cell clonality may be suggestive of
232 adaptive resistance induced by T cell activation and IFN- γ secretion, further supporting
233 our hypothesis.

234 Our study does present certain limitations. First, despite our ability to reproduce
235 several findings from prior studies, our study suffers from a limited sample size, which
236 may have limited our ability to attain statistical significance in certain settings. However,
237 our analysis of 143 samples provides an unprecedented high-resolution analysis of the T
238 cell repertoire in the lungs of NSCLC patients. Second, our analysis of immune
239 phenotypes was unfortunately limited by a lack of tissue availability and a restriction to
240 formalin-fixed paraffin-embedded tissues, preventing us from performing any deeper
241 phenotyping and/or tying TCR sequence to phenotype as has recently been done by
242 others using single cell approaches[24]. Lastly, our analysis of antigen-specificity via
243 GLIPH2.0 remains predictive based on *in silico* analyses and will need to be validated
244 with fresh samples via functional assays, although these were unfortunately unavailable

Spatial heterogeneity of T cell across NSCLC tissues

245 in this context. Nonetheless, our study provides critical information as to the spatial
246 CD4/CD8 T cell composition in the lungs which has not been described by others to date.
247 Overall, our study reveals the exclusion in T cells at play across the lungs of patients with
248 NSCLC, as well as the unique T cell, PD-L1, and pathogen-specific T cell distribution
249 patterns within these patients.

250 **Declarations:**

251 **Ethics approval and consent to participate**

252 The study was approved by the Ethics Committee of Second Xiangya Hospital Central
253 South University (IRB: 2020084).

254 **Consent for publication**

255 All authors have read and approved the article.

256 **Availability of data and material**

257 The authors declare that the data supporting the findings of this study are available within
258 the paper and its Supplementary materials. All data generated during this study are
259 included in this published article and its supplementary information files. All data in this
260 study are available from the corresponding author with a reasonable request.

261 **Competing interests**

262 AR serves on the scientific advisory board and has received honoraria from Adaptive
263 Biotechnologies. Jianjun Zhang reports that grants from Merck, Johnson and Johnson;
264 adversary/consulting/honoraria fees from Bristol Myers Squibb, AstraZeneca, Geneplus,
265 Innovent, OrigMed, Roche outside the submitted work.

Spatial heterogeneity of T cell across NSCLC tissues

266 **Funding**

267 This work was supported by the National Natural Science Foundation of China
268 (81972195 to Dr. Fenglei Yu), Hunan Provincial Key Area R&D Program (2019SK2253
269 to Dr. Fenglei Yu), and the National Clinical Key Specialty Construction Project (to Dr.
270 Fenglei Yu). This investigation was also supported by the Natural Science Foundation of
271 Hunan Province (2022JJ30925 to Yang Gao) and the Project Program of National
272 Clinical Research Center for Geriatric Disorders (Xiangya Hospital, Grant No.
273 2021LNJJ17 to Yang Gao)

274 **Authors' contributions**

275 Qikang Hu, Jianjun Zhang, Xuefeng Xia, Xin Yi, Alexandre Reuben and Fenglei Yu:
276 conception and design, acquisition of data, data analysis and interpretation, manuscript
277 drafting, critical revision; statistical analyses. Meredith Frank, Liyan Ji, Qiongzhi He,
278 Yingqian Zhang and Jianjun Zhang: manuscript drafting. Jianjun Zhang, Yin Yi,
279 Alexandre Reuben and Fenglei Yu: conceived of the idea, supervised this project and
280 revised the manuscript. Meredith Frank, Liyan Ji, Qiongzhi He, Yingqian Zhang,
281 Alexandre Reuben, Muyun Peng, Xiaofeng Chen and Xuefeng Xia: acquisition of data,
282 data analysis and interpretation. Qikang Hu, Yang Gao, Meredith Frank, Muyun Peng,
283 Xiaofeng Chen, Liyan Ji: contributed reagents/materials/analysis tools. Fenglei Yu, Yang
284 Gao: obtained funding.

285 **Acknowledgements**

286 We thank SAN VALLEY DIAGNOSTICS and Servicebio Co. for the assistance with
287 IHC experiments.

Spatial heterogeneity of T cell across NSCLC tissues

288 **List of Abbreviations:**

289 ACT: adoptive cell therapy

290 CDR3: complementarities determining region 3

291 ICB: immune checkpoint blockade

292 ICP: immune cells present

293 IMGT: ImMunoGeneTics

294 MOI: Morisita overlap index

295 NSCLC: non-small cell lung cancer

296 TIL: tumor infiltrating lymphocytes

297 TMB: Tumor mutational burden

298

Spatial heterogeneity of T cell across NSCLC tissues

299 **References**

- 300 1 Al-Shahrabani F, Vallbohmer D, Angenendt S, Knoefel WT Surgical strategies in the
301 therapy of non-small cell lung cancer. *World J Clin Oncol* 2014;5:595-603.
- 302 2 Siegel RL, Miller KD, Fuchs HE, Jemal A Cancer Statistics, 2021. *CA Cancer J Clin*
303 2021;71:7-33.
- 304 3 Gadgeel SM, Ramalingam SS, Kalemkerian GP Treatment of lung cancer. *Radiol Clin*
305 *North Am* 2012;50:961-74.
- 306 4 Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ et al. TCR Repertoire
307 Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with
308 Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. *Cancer Discov*
309 2017;7:1088-97.
- 310 5 Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S et al. Tumor-infiltrating
311 lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. *Nat*
312 *Med* 2021;27:1410-8.
- 313 6 Jiang Z, Zhou Y, Huang J A Combination of Biomarkers Predict Response to Immune
314 Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer. *Front Immunol*
315 2021;12:813331.
- 316 7 Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F et al. Mutational and
317 putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.
318 *Nat Commun* 2017;8:1738.
- 319 8 Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R The Challenges of Tumor
320 Mutational Burden as an Immunotherapy Biomarker. *Cancer Cell* 2021;39:154-73.

Spatial heterogeneity of T cell across NSCLC tissues


- 321 9 Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D et al. Molecular
322 Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed
323 Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer
324 Profiled With Targeted Next-Generation Sequencing. *J Clin Oncol* 2018;36:633-41.
- 325 10 Buttner R, Longshore JW, Lopez-Rios F, Merkelbach-Bruse S, Normanno N, Rouleau
326 E et al. (2019) Implementing TMB measurement in clinical practice: considerations on
327 assay requirements. *ESMO Open*, 2019/02/23 edn. pp. e000442
- 328 11 High TMB Predicts Immunotherapy Benefit. *Cancer Discov* 2018;8:668.
- 329 12 Kim SH, Go SI, Song DH, Park SW, Kim HR, Jang I et al. Prognostic impact of CD8
330 and programmed death-ligand 1 expression in patients with resectable non-small cell lung
331 cancer. *Br J Cancer* 2019;120:547-54.
- 332 13 Feldmeyer L, Hudgens CW, Ray-Lyons G, Nagarajan P, Aung PP, Curry JL et al.
333 Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in
334 Merkel Cell Carcinoma. *Clin Cancer Res* 2016;22:5553-63.
- 335 14 Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC et al. Comprehensive T
336 cell repertoire characterization of non-small cell lung cancer. *Nat Commun* 2020;11:603.
- 337 15 Tian P, Zeng H, Ji L, Ding Z, Ren L, Gao W et al. Lung adenocarcinoma with ERBB2
338 exon 20 insertions: Comutations and immunogenomic features related to
339 chemoimmunotherapy. *Lung Cancer* 2021;160:50-8.
- 340 16 Han J, Yu R, Duan J, Li J, Zhao W, Feng G et al. Weighting tumor-specific TCR
341 repertoires as a classifier to stratify the immunotherapy delivery in non-small cell lung
342 cancers. *Sci Adv* 2021;7.

Spatial heterogeneity of T cell across NSCLC tissues

- 343 17 Huang H, Wang C, Rubelt F, Scriba TJ, Davis MM Analyzing the Mycobacterium
344 tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-
345 wide antigen screening. *Nat Biotechnol* 2020;38:1194-202.
- 346 18 Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW et al. Bystander
347 CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates.
348 *Nature* 2018;557:575-9.
- 349 19 Scheper W, Kelderman S, Fanchi LF, Linnemann C, Bendle G, de Rooij MAJ et al.
350 Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers.
351 *Nat Med* 2019;25:89-94.
- 352 20 Sharma P, Allison JP The future of immune checkpoint therapy. *Science* 2015;348:56-
353 61.
- 354 21 Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E et al.
355 Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. *ESMO*
356 *Open* 2017;2:e000213.
- 357 22 Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C et al.
358 Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of
359 anti-PD-1 treatment. *Proc Natl Acad Sci U S A* 2018;115:E4041-e50.
- 360 23 Spranger S Mechanisms of tumor escape in the context of the T-cell-inflamed and the
361 non-T-cell-inflamed tumor microenvironment. *Int Immunol* 2016;28:383-91.
- 362 24 Liu B, Hu X, Feng K, Gao R, Xue Z, Zhang S et al. Temporal single-cell tracing
363 reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1
364 therapy in lung cancer. *Nat Cancer* 2022;3:108-21.
- 365

Spatial heterogeneity of T cell across NSCLC tissues

366 **Figure**



367

368 Figure 1 A: Schematic representation of experiment design. B: Tissue samples from a


369 total of 6 regions were analyzed for TCR repertoire metrics across n=21 patients. C:

370 Heatmap of clinical characteristics and tumor mutational data of top 20 mutated genes

371 across n=21 patients.

372

Spatial heterogeneity of T cell across NSCLC tissues




373

374 Figure 2A: CD8+ cell density (cells/mm²) measured by IHC across all tissues for n=5
 375 patients. B: CD4+ cell density (cells/mm²) measured by IHC across all tissues for n=5
 376 patients. C: PD-L1 score measured by IHC across all tissues for n=5 patients. D: Median
 377 CD8+: CD4+ cell densities (cells/mm²) across all regions for n=5 patients.

378

Spatial heterogeneity of T cell across NSCLC tissues




379

380 Figure 3A: Morisita overlap values were calculated between tumor and normal tissue for
 381 $n=21$ patients. From top to bottom: tumor, tumor edge, 1cm, 2cm, 5cm , 10cm from
 382 tumor, peripheral blood, respectively. From left to right: tumor, tumor edge, 1cm, 2cm,
 383 5cm, 10cm from tumor, peripheral blood. In most patients, the greatest amount of overlap
 384 was seen between normal tissues peripheral to the tumor, namely, the tumor edge, 1cm,
 385 2cm, and 5cm. The lowest amount of overlap was seen between tumor tissue and
 386 remaining tissues. 3B: Average morisita overlap between regions for $n=21$ patients. From
 387 top to bottom: tumor, tumor edge, 1cm, 2cm, 5cm , 10cm from tumor, peripheral blood,
 388 respectively. From left to right: tumor, tumor edge, 1cm, 2cm, 5cm, 10cm from tumor,
 389 peripheral blood. 3C: Clonality values for all samples for $n=21$ patients. 3D: Median
 390 clonality across regions for $n=17$ patients. 3E: Median Shannon index values across
 391 regions for $n=17$ patients. 3F: Clonality vs PD-L1 expression (all tissues combined).
 392 Pearson's coefficient was used to analyze the association between clonality and PD-L1
 393 expression across all tissues for $n=5$ patients. 3G: Clonality vs PD-L1 expression

Spatial heterogeneity of T cell across NSCLC tissues

394 (stratified by tissues). Pearson's coefficient was used to analyze the association between
 395 clonality and PD-L1 expression across all tissues for n=5 patients.
 396



397
 398 Figure 4A: Percentage of predicted pathogen TCRs across all regions for n=21 patients.
 399 4B: Median percentage of predicted pathogen TCRs across all regions for n=21
 400 patients. 4C: Regional clonality values were plotted against median proportion of
 401 predicted pathogen TCRs for all tissues. The solid line represents correlation between
 402 clonality and predicted pathogen TCRs. Thin dotted lines represent the 95% confidence
 403 interval. 4D: Predicted pathogen TCRs (absolute count) vs. CD4+ cell density (cells/mm²)
 404 for tumor tissue. Pearson's coefficient was used to analyze the association between the
 405 number of predicted pathogen specific TCRs and CD4+ cell density in tumor tissue for
 406 n=5 patients. 4E: Predicted pathogen TCRs (absolute count) vs. clonality for tumor tissue.
 407 Pearson's coefficient was used to analyze the association between the number of
 408 predicted pathogen TCRs and clonality in tumor tissue for n=5 patients. 4F: Predicted
 409 pathogen TCRs (absolute count) vs. CD8+ cell density (cells/mm²) for tumor tissue.

Spatial heterogeneity of T cell across NSCLC tissues

410 Pearson's coefficient was used to analyze the association between the number of
411 predicted pathogen specific TCRs and CD8+ cell density in tumor tissue for n=5
412 patients. 4G: PD-L1 score vs. proportion of predicted pathogen-specific TCRs. Pearson's
413 coefficient was used to analyze the association between PD-L1 score and proportion of
414 predicted pathogen specific TCRs in tumor tissue for n=5 patients.